Contents
1. Acceptance of Applications
1.1 Overview of Applications 1.2 Acceptance of Innovator Drug Applications 1.3 Accepted TCM Applications Requiring Technical Review 1.4 Accepted Chemical Drug Applications Requiring Technical Review 1.5 Accepted Biological Product Applications Requiring Technical Review2. Review of Applications
3. Approval of Applications
3.1 Overview of Approval/Recommended Approval 3.2 Approval of Innovator Drug Applications 3.3 Approval/Recommended Approval of TCM Applications 3.4 Approval/Recommended Approval of Chemical Drug Applications 3.5 Approval/Recommended Approval of Biological Product Applications4. Expedited Approval
4.1 Breakthrough Therapy Designation (BTD) 4.2 Conditional Approval (CA) 4.3 Priority Review (PR) 4.4 Special Approval (SA)5. Onsite Inspections
6. Medical Products in Significant Therapeutic Areas
7. Disapproval Reasons
7.1 R&D Problems 7.2 Efficacy Problems 7.3 Safety Problems 7.4 Problems in Quality Controllability 7.5 Compliance Problems 7.6 Other Problems8. Reforms of the Drug Review & Approval System
8.1 Promoting Pediatric Drugs' Innovative Development 8.2 Improving Clinical Trial Administration and Clinical Research Quality 8.3 Establishing China Marketed Drug Patent Registration Platform 8.4 Stepping Up Quality and Therapeutic Equivalence Evaluations 8.5 Improving Transparency in Drug Review and Approval 8.6 Driving the Digitalization of Drug Applications To see the preview or download the report, please [read full content].Contact Us
BaiPharm, a subsidiary of REACH24H Consulting Group, is specialized in pharmaceutical industry consultancy services. With our experts across China, Japan, South Korea, the United States, and Europe, BaiPharm is fully qualified to engage in complex market entry projects of finished drugs, APIs, excipients, and packaging materials for most key markets. If you have any questions about pharmaceutical regulatory compliance in China, please feel free to contact us. Tel: +86 (0)571-87007555 Email: customer@reach24h.com
